Dihexa (Oral) vs P21
A side-by-side research comparison of Dihexa (Oral) and P21 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Dihexa (Oral) | P21 |
|---|---|---|
| Full name | Dihexa (N-hexanoic-Tyr-Ile-(6) Aminohexanoic Amide) | P21 (CNTF-Derived Tetrapeptide) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research compound |
| Mechanism | Activates hepatocyte growth factor (HGF) / c-Met receptor system in the brain, triggering dendritic spine formation, synaptogenesis, and neuronal survival. This creates new neural pathways for learning and memory. | Mimics CNTF neurogenesis-enhancing portion by increasing BDNF and activating PI3K/Akt. Inhibits LIF signaling to selectively promote neural stem cell proliferation. |
| Molecular weight | 507.63 Da | ~450 Da |
| Half-life | ~12 hours | 4-6 hours |
| Bioavailability | ~70% oral, ~60% intranasal | Moderate (crosses BBB) |
| Typical dose | 10-20 mg | 50-100 mcg/kg |
| Frequency | Daily or every other day | Daily |
| Route | Oral capsule or sublingual | Intranasal or Subcutaneous |
Dihexa (Oral) reported benefits
- Synaptogenesis (new brain connections)
- Dramatic memory enhancement
- Learning acceleration
- Neuroprotection
- Cognitive recovery after injury
P21 reported benefits
- Hippocampal neurogenesis
- BDNF increase
- Cognitive enhancement
- BBB penetrant
- No appetite suppression
- Dendritic branching
Related comparisons
Research and educational reference only. Not medical advice.